Elcelyx Therapeutics
CompanyUnited States
Elcelyx Therapeutics develops one asset, in phase 1 (EFB0027 in type 2 diabetes). Mostly small molecule acting on Mitochondrial biogenesis (PGC-1α) and AMPK signalling; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
1Gut-restricted delayed-release formulation of metformin targeting the lower bowel.
Phase 1, Small molecule, Mitochondrial biogenesis (PGC-1α), AMPK signalling, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Similar companies6